Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Xeloda (Capecitabine),XelodaStudy001,2021,USA,MDV,350,68,62,38,27.5,32,85,5,15,40,30,15,55,25,15,5,20,45,30,18,7,4,9,6,22,68,45,FEC,Docetaxel,CMF,AC,25,35,30,40,55,65,15,45,40,60,2
Xeloda (Capecitabine),XelodaStudy002,2022,Canada,Claim Database,420,72,58,42,28.1,28,78,7,12,38,35,15,50,30,15,5,18,42,35,20,8,5,10,7,25,70,48,EC,Taxol,CAF,AT,28,32,33,45,60,70,18,42,40,65,3
Xeloda (Capecitabine),XelodaStudy003,2023,UK,MDV,280,70,60,40,26.9,30,82,6,14,39,32,15,52,28,16,4,19,43,33,19,7,4,9,6,23,69,46,CEF,Doxetacel,FAC,TC,26,34,31,42,57,67,16,44,40,62,2
